If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
KE Holdings Inc. (BEKE)
RedBall Acquisition Corp. (RBAC.U)
Upcoming IPO
Vistas Media Acquisition (VMACU)
Hitek Global (HKIT)
Presidio Property Trust (SQFT)
PainReform (PRFX)
PaxMedica (PXMD)
NavSight Holdings (NSH.U)
dMY Technology Group II (DMYD.U)
Duck Creek Technologies, Inc. (DCT)
CureVac B.V. (CVAC)
Dragoneer Growth Opportunities (DGNR.U)
Northern Genesis Acquisition (NGA.U)
Inhibrx, Inc. (INBX)
Harmony Biosciences Holdings, Inc. (HRMY)
Priced IPO
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
Rackspace Technology, Inc. (RXT)
BigCommerce Holdings, Inc (BIGC)
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
More companies

Black Diamond Therapeutics, Inc. (BDTX)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Their goal is to bring precision oncology medicine to a greater number of patients. They target undrugged mutations in patients with genetically-defined cancers. The foundation of their company is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Their proprietary technology platform, which they refer to as their Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow them to i) analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, ii) group these mutations into families and iii) develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. They have designed their lead product candidate, BDTX-189, to block the function of an undrugged family of oncogenic proteins defined by mutations which occur across a range of tumor types, and which affect both the epidermal growth factor receptor, or EGFR, and the tyrosine-protein kinase ErbB-2, or HER2.
David M. Epstein Thomas Leggett
Employees Founded
31 2014


Address: 139 Main Street, Cambridge, MA 02142, US

Telephone: 617-252-0848

Web page:

IPO information

Expected Date 1/30/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $554.8
Revenues (MM) $0
Net Income (Loss) (MM) $-28.4


What do you think will happen with the BDTX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8.9
Shares Revised (MM) 0
Expected offer amount (MM) $151.3
Realized offer amount(MM) $0
JP Morgan/ Jefferies/ Cowen
Canaccord Genuity

Sector: Healthcare

Tweets about $BDTX

Tweets volume:

RT volume:


Google Trends Stats